 | Vol. 15.00 – 9 January, 2024 |
| |
|
|
| Scientists combined persistent labeling with time-series single-cell RNA sequencing to build a real-time, quantitative model of in vivo tissue dynamics for murine bone marrow hematopoiesis. [Cell Stem Cell] |
|
|
|
 | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers showed that transmembrane and immunoglobulin domain containing 2 (TMIGD2), a recently discovered co-stimulatory immune receptor, was aberrantly expressed by human AML cells, and can be used to identify and enrich functional leukemia stem cells. [Nature Communications] |
|
|
|
| Investigators found that Nlrc3, a nucleotide-binding domain leucine-rich repeat containing family gene, was highly expressed in hematopoietic differentiation stages in vivo and vitro and was required in hematopoiesis in zebrafish. [Nature Communications] |
|
|
|
| The authors demonstrated that FLT3 inhibitors increased myeloid maturation with reduced stem/progenitor cell populations in murine fms-like tyrosine kinase 3 (FLT3-ITD) AML. [Leukemia] |
|
|
|
| Investigators established CD34+ cord blood–derived CBFA2T3::GLIS2models that sustained serial transplantation and recapitulated human leukemia regarding immunophenotype, leukemia-initiating cell frequencies, comutational landscape. [Blood Advances] |
|
|
|
| Using an MLL-AF9-induced murine acute myeloid leukemia model, researchers studied the role of hematopoietic cytokines in the survival of lymphoid-primed multipotent progenitor- and granulocyte-monocyte progenitor-like leukemia stem cells. [Stem Cell Reports] |
|
|
|
| MarrowCellDLD enabled the isolation of large, fragile bona marrow-derived cells based on intrinsic size properties while preserving their viability and functionality. [Scientific Reports] |
| |
|
|
| A total of 1344 adult patients received an unmanipulated haploidentical transplant at 37 centers from 2012 to 2019 for hematologic malignancy. Investigators compared the outcomes of patients according to the type of graft, using a propensity score analysis. [Journal Of Hematology & Oncology] |
|
|
|
| Researchers compared outcomes of patients under 18 years with AML in first and second complete remission undergoing a hematopoietic stem cell transplantation (HCT) either with a MUD with anti-thymocyte globuline or a haplo HCT with PT-CY after a myeloablative conditioning regimen between 2011 and 2021. [Haematologica] |
|
|
|
|
| Scientists provide an overview of the zebrafish forward screening approach for hematopoietic gene discovery and highlight the key genes and pathways identified using this method. [Experimental & Molecular Medicine] |
|
|
|
| The authors summarize recent progress in ex vivo HSC expansion technologies and their applications to biological and clinical problems and discusses current questions in the field. [Experimental Hematology] |
|
|
|
|
| Cincinnati Children’s is one of a few centers in the nation to test a novel therapy that uses cytokine-induced memory-like natural killer cells from haploidentical donors to treat AML. This study is open to patients ages 12- 45 years with relapsed or refractory AML who haven’t undergone bone marrow transplantation. [Cincinnati Children’s] |
|
|
|
| Galecto, Inc. announced positive topline results from a Phase IIa trial of GB2064 for the treatment of myelofibrosis. The MYLOX-1 trial dosed a total of 18 myelofibrosis patients. [Galecto, Inc.] |
|
|
|
|
| February 27 – 28, 2024 London, England, United Kingdom |
|
|
|
|
|
| City of Hope – Duarte, California, United States |
|
|
|
| MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| Albert-Ludwigs-University Freiburg – Freiburg im Breisgau, Germany |
|
|
|
| BC Cancer – Vancouver, British Columbia, Canada |
|
|
|
| Karolinska Institutet – Flemingsberg, Sweden |
|
|
|
|